Dendreon Expands Provenge To Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
With the U.S rollout of Provenge well underway, Dendreon outlines its next steps in the U.S. and Europe.
You may also be interested in...
Dendreon Defends Provenge’s Stake Against Arrival Of Abiraterone
Dendreon Corp. is defending Provenge's position as the “foundation of care” for castration-resistant prostate cancer, following the recent approval of Johnson & Johnson’s Zytiga, and looking ahead to other novel drugs coming down the pike.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.